J. Tambiah

发表

Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

L. Arendt-Nielsen, M. Hochberg, V. Kraus, 2022, Osteoarthritis and cartilage open.

CEOR_A_302289 421..435

M. Bonafede, A. Bedenbaugh, E. Marchlewicz, 2021 .

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

M. Hochberg, N. Lane, J. Hood, 2017, Osteoarthritis and cartilage.

Inhibition of Wnt Pathway Activity as a Treatment Approach for Human Osteoarthritis: A Systematic Review

Andrea C. Carrano, C. Lattermann, A. Carrano, 2022, Journal of Cartilage & Joint Preservation.

A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis.

M. Hochberg, N. Lane, T. McAlindon, 2021, Osteoarthritis and cartilage.

Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint

T. McAlindon, C. Swearingen, Y. Yazici, 2022, The American journal of sports medicine.

Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis

V. Strand, P. Taylor, M. Bergman, 2015, The Journal of Rheumatology.

Management in Rheumatoid Arthritis Patient Expectations and Perceptions of Goal-setting Strategies for Disease

V. Strand, P. Taylor, M. Bergman, 2015 .

Osteoarthritis today: Lost in translation?

N. Lane, J. Tambiah, S. Kennedy, 2023, Best practice & research. Clinical rheumatology.

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

B. Melchior, Ch Lai, J. Hood, 2019, Osteoarthritis and cartilage.

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

J. Hood, C. Barroga, M. Ibanez, 2018, Osteoarthritis and cartilage.

Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial

J. Farr, P. Conaghan, C. Swearingen, 2021, Rheumatology and Therapy.

Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

M. Hochberg, N. Lane, D. Clauw, 2020, Arthritis & Rheumatology (Hoboken, N.j.).

Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

M. Hochberg, N. Lane, D. Clauw, 2020, Arthritis & rheumatology.

Efficacy and safety from a phase 2B trial of SM04690, a novel, intra-articular, WNT pathway inhibitor for the treatment of osteoarthritis of the knee

M. Hochberg, N. Lane, T. McAlindon, 2019, Osteoarthritis and Cartilage.

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls

A. Bedenbaugh, E. Marchlewicz, M. Bonafede, 2021, ClinicoEconomics and outcomes research : CEOR.

Results from a 52-week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis

M. Hochberg, N. Lane, D. Clauw, 2018 .

A Phase 2, 104-Week Study Of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, And Bone Health Utlizing Quantitative Computed Tomography In Knee Osteoarthritis (Oa-06)

Y. Yazici, N. Lane, H. Ghandehari, 2023, Osteoarthritis and Cartilage.

OP0188 INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS

M. Hochberg, N. Lane, C. Damatarca, 2020, Annals of the Rheumatic Diseases.

SAT0565 Adjusting for the intra-articular placebo effect in knee osteoarthritis therapies

M. Phillips, I. Simsek, A. Bedenbaugh, 2018, Saturday, 16 JUNE 2018.

FRI0534 Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a wnt pathway inhibitor, sm04690, for knee osteoarthritis treatment

M. Hochberg, T. McAlindon, A. Gibofsky, 2018, Osteoarthritis.

OP0061 Treatment of knee osteoarthritis with sm04690 improved womac a1 ‘pain on walking’ – results from a 52 week, randomised, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, wnt pathway inhibitor

M. Hochberg, C. Swearingen, H. Ghandehari, 2018, WEDNESDAY, 13 JUNE 2018.

SM04755, a small‐molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy

J. Hood, C. Barroga, Y. Yazici, 2020, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.